Solid Tumors Clinical Trials

89 recruiting

Solid Tumors Trials at a Glance

480 actively recruiting trials for solid tumors are listed on ClinicalTrialsFinder across 6 cities in 57 countries. The largest study group is Phase 1 with 385 trials, with the heaviest enrollment activity in Houston, Nashville, and Beijing. Lead sponsors running solid tumors studies include Suzhou Suncadia Biopharmaceuticals Co., Ltd., Jiangsu HengRui Medicine Co., Ltd., and Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd..

Browse solid tumors trials by phase

Treatments under study

About Solid Tumors Clinical Trials

Looking for clinical trials for Solid Tumors? There are currently 89 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Solid Tumors trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Solid Tumors clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 480 trials

Recruiting
Phase 1

A Phase 1 Dose-escalation Trial of KST-6051 in Participants With Advanced Solid Tumors With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Mutation

KRAS-mutant Non-small Cell Lung Cancer (NSCLC)KRAS-mutant Pancreatic Ductal Adenocarcinoma (PDAC)KRAS-mutant Colorectal Cancer (CRC)+1 more
Kestrel Therapeutics, Inc.145 enrolled5 locationsNCT07458347
Recruiting

NCI Childhood Cancer Data Initiative (CCDI) Led Pediatric, Adolescent, and Young Adult Rare Cancer Registry for Very Rare Solid Tumors

Solid TumorOther Solid TumorsVery Rare Tumors+2 more
National Cancer Institute (NCI)4,000 enrolled1 locationNCT07489378
Recruiting
Phase 1

5-aza-4'-Thio-2'-Deoxycytidine (Aza-TdC) in People With Advanced Solid Tumors

Solid TumorsNeoplasms
National Cancer Institute (NCI)65 enrolled1 locationNCT03366116
Recruiting
Phase 1

Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of BL-M05D1 in Subjects With Solid Tumors

Biliary Tract CancerEsophageal AdenocarcinomaGastric Adenocarcinoma+2 more
SystImmune Inc.160 enrolled17 locationsNCT07021066
Recruiting
Phase 1

A Phase 1 Study of AB521 Monotherapy and Combination Therapies in Renal Cell Carcinoma and Other Solid Tumors

Solid TumorsClear Cell Renal Cell Carcinoma
Arcus Biosciences, Inc.362 enrolled25 locationsNCT05536141
Recruiting
Phase 2

A Study of Lirafugratinib in Non-CCA Solid Tumors With FGFR2 Fusion or Rearrangement

Other Solid Tumors, AdultFGFR2 Gene Fusion/Rearrangement
Elevar Therapeutics30 enrolled19 locationsNCT07359820
Recruiting
Early Phase 1

NK521 in the Treatment of Malignant Ascites Associated With Advanced Solid Tumors

Advanced Solid Tumors
Base Therapeutics (Shanghai) Co., Ltd.18 enrolled1 locationNCT07561437
Recruiting
Phase 1Phase 2

Study of Anti-CEACAM5 ADC M9140 in Participants With Advanced Solid Tumors (PROCEADE PanTumor)

Gastric CancerSolid Tumors
EMD Serono Research & Development Institute, Inc.250 enrolled81 locationsNCT06710132
Recruiting
Phase 1

Phase I Study of HSK42360-Na in Solid Tumors With BRAF V600 Mutation

Solid Tumors (Phase 1)
Haisco Pharmaceutical Group Co., Ltd.159 enrolled2 locationsNCT07561554
Recruiting
Phase 1Phase 2

A First-In Human (FIH) Study to Find Out How Well REGN10597 Medicine Given Alone or in Combination With Cemiplimab Works in Adult Participants Who Have Cancer With Tumors That Have Spread in Their Body

MelanomaAdvanced Solid TumorsClear-Cell Renal-Cell Carcinoma (ccRCC)
Regeneron Pharmaceuticals240 enrolled11 locationsNCT06413680
Recruiting
Phase 2

A Study to Evaluate the Safety and Pharmacokinetics of Eflapegrastim in Pediatric Participants With Solid Tumors or Lymphomas and Treated With Myelosuppressive Chemotherapy

Solid TumorsLymphoma
Spectrum Pharmaceuticals, Inc40 enrolled5 locationsNCT04570423
Recruiting
Phase 1Phase 2

Study of ECI830 Single Agent or in Combination in Patients With Advanced HR+/HER2- Breast Cancer and Other Advanced Solid Tumors

Advanced HR+/HER2- Breast CancerAdvanced CCNE1-amplified Solid Tumors
Novartis Pharmaceuticals280 enrolled33 locationsNCT06726148
Recruiting
Phase 1

A Phase I Study of SY-9453 in Patients With Advanced Solid Tumors

Advanced or Metastatic Solid Tumors With Homozygous MTAP Deletion
Shouyao Holdings (Beijing) Co. LTD122 enrolled1 locationNCT07469982
Recruiting

Natural History and Biospecimen Acquisition for Children and Adults With Rare Solid Tumors

Solid TumorPediatric Solid TumorMalignant Solid Tumors+2 more
National Cancer Institute (NCI)10,000 enrolled3 locationsNCT03739827
Recruiting
Phase 1

A Study of DXC014 in Patients With Advanced Solid Tumors.

Prostate CancerMelanomaSmall Cell Lung Cancer+1 more
Hangzhou DAC Biotechnology Co., Ltd.150 enrolled3 locationsNCT07177937
Recruiting
Phase 1

A Study of DXC008 in Patients With Prostate Cancer and Other Solid Tumors

Prostate CancerEwing SarcomaOther Solid Tumors
Hangzhou DAC Biotechnology Co., Ltd.110 enrolled3 locationsNCT06926283
Recruiting
Phase 1

A Study of MGC028 in Participants With Advanced Solid Tumors

CholangiocarcinomaColorectal CarcinomaPancreatic Carcinoma+2 more
MacroGenics124 enrolled7 locationsNCT06723236
Recruiting
Phase 3

Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587)

Solid TumorsHematologic Malignancies
Merck Sharp & Dohme LLC3,500 enrolled779 locationsNCT03486873
Recruiting
Phase 1Phase 2

A Study of TAK-188 in Adults With Advanced or Spreading Solid Tumors

Advanced or Metastatic Solid Tumors
Takeda223 enrolled15 locationsNCT07205718
Recruiting
Phase 1

A Phase I Study to Investigate the Safety and Tolerability of KGX101 Monotherapy and Combination Therapy With Envafolimab in Advanced or Metastatic Solid Tumor Patients

Advanced or Metastatic Solid Tumors
Kangabio AUSTRALIA LTD PTY57 enrolled3 locationsNCT07260305